法国赛诺菲的喜保宁功效和作用

The generic name is vigabatrin, and the brand name is Sabril. It is a drug used to treat epilepsy and infantile spasms. It was developed by Sanofi of France and was approved for treatment in the UK in 1989. Let’s learn about the efficacy and role of Vigabatrin from Sanofi of France.

France's Sanofi's Vigabatrin is usually used for partial seizures of epilepsy and can also be used in combination with other anti-epileptic drugs to treat refractory epilepsy. It can also be used for children with Lennox-Gastaut syndrome and West syndrome (infant pain syndrome). It is not effective for epileptic seizures and muscle spasms. It needs to be taken under the guidance of a physician.

Vigabatrin is an analog of gamma-aminobutyric acid (GABA). It can specifically bind to GABA aminotransferase and irreversibly, leading to an increase in GABA concentration in the brain, thus exerting anti-epileptic effects. Vigabatrin is used as adjunctive therapy in patients who are refractory to other antiepileptic drugs, especially those with partial seizures (mainly used to control complex partial seizures). Vigabatrin may worsen absence seizures or myoclonic seizures. Vigabatrin may also be used in infants with West syndrome (infantile spasms), which is generally unresponsive to conventional antiepileptic drugs. As an auxiliary treatment drug, it can achieve better curative effect. When used alone, it is effective in the treatment of newly diagnosed patients.

Recommended hot articles: /newsDetail/95604.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.